Cell News and Research

RSS

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Time magazine declares NYSCF member as 2010 "Person who Matters" for innovative stem cell research

The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.

22 Dec 2010

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

New research sheds light on how neurons make connections with one another

Newly published research led by Professor Z. Josh Huang, Ph.D., of Cold Spring Harbor Laboratory sheds important new light on how neurons in the developing brain make connections with one another.

22 Dec 2010

New online tool helps scientists to find gene promoters

Researchers at The Wistar Institute announce the release of an online tool that will help scientists find "gene promoters"—regions along a DNA strand that tell a cell's transcription machinery where to start reading in order to create a particular protein.

22 Dec 2010

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Parents most influence teens' decisions about sex

The teen birth rate in the United States declined 6% in 2009 and is now at a record low, according to new data released today by the Centers for Disease Control and Prevention's National Center for Health Statistics. Rates declined among older and younger teens and among all racial and ethnic groups. For example, the birth rate among Hispanic teens declined 10% in 2009 and is now at a record low.

22 Dec 2010

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

The day when an ovarian cancer patient can treat her tumor with a single, painless pill instead of a toxic drug cocktail is the ultimate goal of the pioneering research of a University of Houston scientist.

22 Dec 2010

Vitrolife receives FDA approval for RapitVit Blast and RapidWarm Blast vitrification products

Vitrolife has received approval from the U.S. Food and Drug Administration, FDA, the equivalent of the Swedish Medical Products Agency, for the products RapitVit™ Blast and RapidWarm™ Blast. So-called 510(k) clearance has been obtained for these products, which are used for so-called vitrification, the rapid freezing and thawing of blastocysts (embryos days 5-7 after fertilization). Vitrolife has since before approved products for vitrification of embryos in an earlier stage of the fertilization (embryos day 2-3 after fertilization).

22 Dec 2010

People with type 1 diabetes could grow their own insulin-producing cells, say researchers

At the annual meeting of the American Society for Cell Biology last week in Philadelphia, researchers from Georgetown University Medical Center in Washington, D.C., announced that it may be possible for people with type 1 diabetes to grow their own insulin-producing cells, a breakthrough that could lead to a cure for the disease.

22 Dec 2010

High LSC scores associated with adverse outcomes in AML patients

In an examination of leukemic stem cells (LSC), researchers have found that patients with acute myeloid leukemia who had higher activity of certain LSC genes had worse overall, event-free and relapse-free survival, according to a study in the December 22/29 issue of JAMA.

21 Dec 2010

New genetic alteration predisposes individuals to Cowden syndrome

Researchers have identified a new genetic alteration that predisposes individuals to Cowden syndrome, a rare disorder that is characterized by high risks of breast, thyroid and other cancers, according to preliminary research published in the December 22/29 issue of JAMA.

21 Dec 2010

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival.

21 Dec 2010

Chronic fatigue syndrome not linked to virus

The latest research from the University College London, the Wellcome Trust Sanger Institute, and University of Oxford, England suggests that chronic fatigue syndrome (CFS) is not caused by the virus XMRV (xenotropic murine leukemia virus-related virus). The team says that earlier research that linked the virus to CFS was faulty because of contamination of mouse cell DNA samples in the laboratory.

21 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.

21 Dec 2010

Researchers present definitive explanation of how fibrotic cells destroy human liver

In the latest of a series of related papers, researchers at the University of California, San Diego School of Medicine, with colleagues in Austria and elsewhere, present a new and more definitive explanation of how fibrotic cells form, multiply and eventually destroy the human liver, resulting in cirrhosis. In doing so, the findings upend the standing of a long-presumed marker for multiple fibrotic diseases and reveal the existence of a previously unknown kind of inflammatory white blood cell.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Cell News and Research

Top ten advances in cardiovascular, stroke research in 2010

Time magazine declares NYSCF member as 2010 "Person who Matters" for innovative stem cell research

Therapies to target self-renewing population of chemotherapy-resistant cells needed

New research sheds light on how neurons make connections with one another

New online tool helps scientists to find gene promoters

Amorcyte reports AMR-001 phase I trial results in heart attack patients

Parents most influence teens' decisions about sex

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

Vitrolife receives FDA approval for RapitVit Blast and RapidWarm Blast vitrification products

People with type 1 diabetes could grow their own insulin-producing cells, say researchers

High LSC scores associated with adverse outcomes in AML patients

New genetic alteration predisposes individuals to Cowden syndrome

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

Chronic fatigue syndrome not linked to virus

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

Researchers present definitive explanation of how fibrotic cells destroy human liver

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

Gilenya offers more benefits for MS therapy than previously realized

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics